Karyopharm Therapeutics Inc
Price
FilingsNewest: 8-K, Change to holders' rightsSep 18 →InsidersNo open-market buys. 7 insiders sold $347,944, 0 of 17 sales on a 10b5-1 plan.→HoldersRa 8.5%Adage Capital Partners GP 6.7%Acorn Capital 6.7%→Financing →PeersClosest companies: CRIS, BBIO, ROIV→
From the filings
Figures
- Revenue
- $146.6Mlast 12 months
- Net income
- −$224.7Mlast 12 months
- Operating cash flow
- −$59.1Mlast 12 months
- Cash and equivalents
- $55.0Mat the last balance sheet
- Shares outstanding
- 22.7M shareson issue